Ruth Riisnaes
0000-0002-8924-302X
21 papers found
Refreshing results…
A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Missing publications? Search for publications with a matching author name.